This dual role not only underscores the potential impact of USP11 inhibition in CRC but also suggests that USP11 inhibitors may offer a targeted therapeutic strategy for CRC cases characterized by dysregulated EGFR and TLR pathways. This evidence concerns the gene EGFR and colorectal carcinoma.